OTCMKTS:EMBI Emerald Bioscience (EMBI) Stock Price, News & Analysis → 😱 This phenomenon is smashing regular market gains (From MillPub) (Ad) Free EMBI Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range$0.09▼$17.7552-Week Range N/AVolume6.96 million shsAverage Volume14.24 million shsMarket Capitalization$24.13 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Emerald Bioscience alerts: Email Address Ad InvestorPlaceElon’s New A.I. Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. About Emerald Bioscience Stock (OTCMKTS:EMBI)Emerald Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111, which is in preclinical trials for the treatment of glaucoma. It is also developing NB2222, a product candidate in preclinical trials for use in the treatment of various eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3111, a cannabinoid cocktail in testing for use as an anti-infective agent against various strains of antibiotic resistant bacteria, including methicillin-resistant Staphylococcus aureus. The company was formerly known as Nemus Bioscience, Inc. and changed its name to Emerald Bioscience, Inc. in March 2019. Emerald Bioscience, Inc. was founded in 2012 and is based in San Diego, California.Read More Ad InvestorPlaceElon’s New A.I. Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. EMBI Stock News HeadlinesApril 19, 2024 | morningstar.comSprint Bioscience AB SPRINTApril 16, 2024 | benzinga.comCannabis Bioscience Stock (OTC:CBIH), Quotes and News SummaryMay 1, 2024 | Porter & Company (Ad)Truth about Trump you’ve never heardEverything about Donald Trump is public. Every part of his life has been dragged out in the media. But there’s one story I bet you’ve never heard about Trump. February 21, 2024 | finance.yahoo.comDaré Bioscience, Inc. (DARE)January 17, 2024 | wsj.comStar Lake Bioscience Co. Ltd. Guangdong Zhaoqing ANovember 15, 2023 | lse.co.ukBnp Paribas Easy Jpm Esg Embi Global Diversified Composite Ucits Etf H Eur Cap Share Price (EMBH.PA)September 6, 2023 | bizjournals.comConstruction starts on $55M senior living project in RedmondFebruary 21, 2023 | duluthnewstribune.comDuluth takes less aggressive stance against emerald ash borers, prepares to cutMay 1, 2024 | Porter & Company (Ad)Truth about Trump you’ve never heardEverything about Donald Trump is public. Every part of his life has been dragged out in the media. But there’s one story I bet you’ve never heard about Trump. July 11, 2022 | finance.yahoo.comEmerald Health Therapeutics, Inc. Reports 2022 Q1 ResultsSee More Headlines Receive EMBI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Emerald Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry N/A Sub-IndustryN/A Current SymbolOTCMKTS:EMBI CUSIPN/A CIKN/A Webwww.emeraldbio.life Phone949-336-3443FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$1.05 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-347.62% Debt Debt-to-Equity Ratio0.43 Current Ratio3.59 Quick Ratio3.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares268,074,000Free FloatN/AMarket Cap$24.13 million OptionableNot Optionable Beta0.43 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Punit S. Dhillon B.A. (Age 40)BA, Exec. Chairman & CEO Comp: $65kMr. Richard JanneyInterim Principal Accounting OfficerMs. Elena Traistaru (Age 61)Company Sec. Key CompetitorsNephrosNASDAQ:NEPHFG GroupNYSEAMERICAN:FGHInspira Technologies Oxy B.H.N.NASDAQ:IINNExagenNASDAQ:XGNBullfrog AINASDAQ:BFRGView All Competitors EMBI Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Emerald Bioscience own? Based on aggregate information from My MarketBeat watchlists, some companies that other Emerald Bioscience investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Charlotte's Web (CWBHF), Akero Therapeutics (AKRO), CymaBay Therapeutics (CBAY), Cognex (CGNX), Cumberland Pharmaceuticals (CPIX), Corbus Pharmaceuticals (CRBP) and Editas Medicine (EDIT). How do I buy shares of Emerald Bioscience? Shares of EMBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:EMBI) was last updated on 5/1/2024 by MarketBeat.com Staff From Our Partners😱 This phenomenon is smashing regular market gainsMillPubYour bank is lying to you.MyBankTracker#1 election stockPorter & CompanyBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingBiden out June 13; Kamala won’t replace him?Paradigm Press4 coins to be the “Next Bitcoin”True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emerald Bioscience Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.